These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17713991)

  • 1. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
    Kaa K
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer: complexities and challenges in managed care.
    Minkoff NB
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S27-9. PubMed ID: 17713992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy.
    Carino T; Williams RD; Colbert AM; Bridger P
    Health Aff (Millwood); 2006; 25(5):1231-9. PubMed ID: 16966718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the Medicare Prescription Drug Improvement and Modernization Act on the management of colorectal cancer.
    Siegel J
    Am J Health Syst Pharm; 2006 May; 63(9 Suppl 2):S18-21. PubMed ID: 16641253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Part D: selected issues for pharmacists and beneficiaries in 2007.
    Kilian J; Stubbings J
    J Manag Care Pharm; 2007; 13(1):59-65. PubMed ID: 17269838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations.
    Daval CJR; Kesselheim AS
    JAMA Intern Med; 2023 Sep; 183(9):999-1004. PubMed ID: 37505487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking at CER from Medicare's perspective.
    Mohr P
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S5-8. PubMed ID: 22578211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursement for cancer treatment: coverage of off-label drug indications.
    American Society of Clinical Oncology
    J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forcing isolation: Medicare's "in the home" coverage standard for wheelchairs.
    Medicare Rights Center
    Care Manag J; 2005; 6(1):29-37. PubMed ID: 16447855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare coverage for oncology services.
    Bagley GP; McVearry K
    Cancer; 1998 May; 82(10 Suppl):1991-4. PubMed ID: 9587095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare Part D-a roundtable discussion of current issues and trends.
    Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
    J Manag Care Pharm; 2009; 15(1 Suppl A):3-9. PubMed ID: 19125555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
    Gordan L; Grogg A; Blazer M; Fortner B
    J Oncol Pract; 2017 Feb; 13(2):e139-e151. PubMed ID: 28029298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paying for Cancer Drugs That Prove Their Benefit.
    Frank RG; Emanuel EJ
    JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new Medicare bill: far-reaching effects on cancer treatment.
    Bailes JS; Coleman T
    Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Government and private insurance medical programs as well as MDVIP, an update.
    Edlich RF; Winters KL; Brit LD; Long WB
    J Long Term Eff Med Implants; 2004; 14(3):243-50. PubMed ID: 15301667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.